A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

August 19, 2019

Primary Completion Date

August 22, 2022

Study Completion Date

September 28, 2022

Conditions
Ebola Virus Disease
Interventions
BIOLOGICAL

Ad26.ZEBOV

Participants will receive 0.5 mL IM injection of Ad26.ZEBOV as first vaccination.

BIOLOGICAL

MVA-BN-Filo

Participants will receive 0.5 mL IM injection of MVA-BN-Filo as second vaccination.

BIOLOGICAL

MenACWY

Participants will receive 0.5 mL IM injection of MenACWY.

Trial Locations (2)

2649

Centre National de Formation et de Recherche en Sante Rurale de Maferinyah, Conakry

Unknown

College of Med and Allied Health Sciences, University of Sierra Leone, Freetown

All Listed Sponsors
collaborator

London School of Hygiene and Tropical Medicine

OTHER

collaborator

University of Sierra Leone

OTHER

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT03929757 - A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants | Biotech Hunter | Biotech Hunter